当前吸烟的慢阻肺患者吸入激素治疗反应降低:FLAME试验分析
该研究为FLAME试验的事后分析,探讨吸烟状态对LABA+ICS与LABA+LAMA预防慢阻肺急性加重疗效的影响。结果提示,在当前吸烟者中LABA+LAMA预防中重度急性加重优于LABA+ICS;在嗜酸性粒细胞≥200 cells/µL的戒烟者中则LABA+ICS更优,吸烟状态显著改变ICS的治疗效应。
要点
- 当前吸烟的慢阻肺患者使用LABA+LAMA预防中重度急性加重优于LABA+ICS。
- 戒烟且血嗜酸性粒细胞≥200 cells/µL者,LABA+ICS优于LABA+LAMA。
- 吸烟状态显著影响ICS对急性加重结局的疗效。
核心结论
- 吸烟状态显著改变ICS对慢阻肺急性加重结局的治疗效应,当前吸烟者ICS疗效降低,且与血嗜酸性粒细胞计数无关。
研究设计与样本
- FLAME试验的事后分析,比较LABA+ICS与LABA+LAMA预防急性加重的疗效,按吸烟状态分层。
主要发现
- 当前吸烟者中,LABA+LAMA预防中重度急性加重优于LABA+ICS。
- 戒烟且血嗜酸性粒细胞≥200 cells/µL者中,LABA+ICS优于LABA+LAMA。
关键数值与推荐
- 戒烟者血嗜酸性粒细胞≥200 cells/µL时LABA+ICS更优;当前吸烟者无论血嗜酸性粒细胞计数如何,ICS疗效均降低。
临床怎么用
- 对当前吸烟的慢阻肺患者,选择含ICS方案前应评估吸烟状态,优先考虑LABA+LAMA。
- 对戒烟且血嗜酸性粒细胞≥200 cells/µL者,可考虑LABA+ICS。
局限性
- 本研究为FLAME试验的事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inhaled corticosteroids (ICSs) benefit patients with chronic obstructive pulmonary disease at high risk of exacerbations with raised blood eosinophil count (BEC). Emerging evidence suggests current smokers show a reduced response to ICS. This post-hoc analysis of the FLAME trial explored the impact of smoking status on the efficacy of long-acting beta-2 agonist (LABA)+ICS versus LABA+long-acting muscarinic antagonist (LAMA) for preventing exacerbations. Our findings indicate that LABA+LAMA is superior to LABA+ICS in preventing moderate to severe exacerbations in current smokers and inferior in ex-smokers with BEC ≥200 cells/µL. Smoking status significantly modifies ICS treatment effects on exacerbation outcomes, suggesting reduced ICS efficacy in current smokers, regardless of BEC.
引用
- Mathioudakis, Higham, Bate, et al. Reduced treatment response to inhaled corticosteroids in current smokers with COPD, regardless of blood eosinophil count: insights from the FLAME trial. Thorax. 2025. PMID: 40350264. doi:10.1136/thorax-2024-222547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。